Oragenics, Inc.

OGEN

AMEX

Healthcare

Biotechnology

Tampa, FL, US3 employeesoragenics.com

$0.58

+0.03(4.91%)

Mkt Cap $3M

$0.50

$6.06

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Grant (100%).

8-K

Oragenics, Inc. issued a press release on March 10, 2026, announcing receipt of final Human Research Ethics Committee approval. The company filed an 8-K on March 11, 2026, under Item 8.01 Other Information with exhibits including press releases dated March 10 and March 11, 2026.

$3M

Market Cap

—

Revenue

—

Net Income

Employees3

Fundamentals

How The Business Makes Money

Revenue by Segment

Grant100%($250.0K)

Activity

What Changed Recently

Material Agreement

Jan 21, 2026

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. As previously disclosed, on October 11, 2024, Oragenics, Inc. (the “ Company ”) entered into an At-the-Market Sales

Exhibits Only

Mar 30, 2026

. FINANCIAL STATEMENTS AND EXHIBITS.** (d) Exhibits | Exhibit No. | | Description | |---|---|---| | | | | | 104 | | Cover page Interactive Data File (embedded i

Other Event

Mar 10, 2026

. OTHER INFORMATION. On March 10, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it had received final Human Research Ethics Commi

Regulation FD

Jan 19, 2026

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen

Peer Companies

Company	Price	Change	Market Cap	P/E
KZIAKazia Therapeutics Limite...	$7.27	+1.25%	$12M	-1.4
SNGXSoligenix, Inc.	$1.14	-0.87%	$11M	-0.5
QLGNQLGN	$3.21	+5.59%	$5M	—
XBIOXenetic Biosciences, Inc.	$2.98	+5.50%	$5M	-2.7
KALAKALA BIO, Inc.	$0.17	+4.11%	$4M	-0.0
TTNPTTNP	$2.34	-11.36%	$3M	—
AIMAIM ImmunoTech Inc.	$0.60	+9.05%	$2M	—
CANFCan-Fite BioPharma Ltd.	$3.10	+0.49%	$2M	—

Analyst View

Company Profile

CIK0001174940

ISINUS6840236094

CUSIP684023609

Phone813 286 7900

Address4902 Eisenhower Boulevard, Tampa, FL, 33634, US

SEC EDGAR